SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MGX

Metagenomi Therapeutics, Inc. (NASDAQ:MGX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.58-$0.04 (-5.85%)
 
Market cap
$21.8M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 9, 2024
Market Cap$21.85M-61.7%
Revenue (ttm)$7.09M-77.1%
Net Income-$94.19M-6.1%
EPS-$2.50-4.2%
Shares Out37.81M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume157,752.568
Open$0.62
Previous Close$0.61
Day's Range$0.57 - $0.62
52-Week Range$0.57 - $1.87
Beta0.67
AnalystsBuy
Price Target$14.50(+2409.08%)
Earnings DateMar 4, 2027
-5.51% (1D)
No price history available.

About MGX

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Address
5959 Horton Street, Emeryville, CA, 94608, US
Market Cap
22 million
Employees
113
Industrial Classification
Biotechnology

Metagenomi Therapeutics, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
40th Percentile Overall Score
MGX InsiderScore:64 / 99

Metagenomi Therapeutics, Inc. scored higher than 40% of companies evaluated by InsiderBuying, and ranked 46th out of 102 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Metagenomi Therapeutics, Inc. bought $23.4K of stock across 2 purchases in the last 90 days, the largest of them $23.3K.

Stake Increase

The average purchase added about 1% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$44.07K
Bought
$23.40K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From MGX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.85%
5 Days
-19.06%
1 Month
-30.48%
6 Months
-55.20%
1 Year
-61.73%

$MGX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MGX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MGX's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MGX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

MGX Revenue by Segment

$12.94MTotal
Facilities and overhead costs$6.28M48.57%
Professional services and consulting$3.20M24.76%
Ionis$2.20M17.01%
Interest and other$1.10M8.50%
Affini-T$125.00K0.97%
Other$25.00K0.19%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New MGX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MGX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in MGX

VTIVanguard Morningstar Total Stock Market ETF$455.89K
VXFVanguard Extended Market ETF$246.15K
IWCiShares Micro-Cap ETF$53.21K
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF$20.00K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from MGX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
46.77
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: FDA clearance for lead program and Q3 results announcement drive bullish sentiment; conference presentation supports positive visibility.

Recent Insider Activity

Buys
2
Sells
17
Buy Value
$23.40K
Distinct Buyers
1

Insider Score Trend Over Time

-3.9 since Sep 16
0255075100Sep 16 — Insider Score 70.2Sep 17 — Insider Score 69.0Sep 18 — Insider Score 69.0Sep 19 — Insider Score 68.6Sep 20 — Insider Score 68.6Sep 21 — Insider Score 68.3Sep 22 — Insider Score 67.2Sep 23 — Insider Score 66.3Sep 24 — Insider Score 65.4Sep 25 — Insider Score 80.3Sep 26 — Insider Score 80.3Sep 27 — Insider Score 80.5Sep 28 — Insider Score 80.6Sep 29 — Insider Score 80.0Sep 30 — Insider Score 79.7Oct 1 — Insider Score 79.1Oct 2 — Insider Score 39.0Oct 3 — Insider Score 78.9Oct 4 — Insider Score 79.0Oct 5 — Insider Score 79.1Oct 6 — Insider Score 78.3Oct 7 — Insider Score 78.0Oct 8 — Insider Score 77.9Oct 9 — Insider Score 77.8Oct 10 — Insider Score 77.2Oct 11 — Insider Score 78.0Oct 12 — Insider Score 78.0Oct 13 — Insider Score 77.7Oct 14 — Insider Score 77.2Oct 15 — Insider Score 77.2Oct 16 — Insider Score 77.6Oct 17 — Insider Score 77.3Oct 18 — Insider Score 77.6Oct 19 — Insider Score 77.5Oct 20 — Insider Score 77.3Oct 21 — Insider Score 76.6Oct 22 — Insider Score 76.6Oct 23 — Insider Score 77.2Oct 24 — Insider Score 77.2Oct 25 — Insider Score 77.0Oct 26 — Insider Score 76.7Oct 27 — Insider Score 76.8Oct 28 — Insider Score 76.0Oct 29 — Insider Score 75.4Oct 30 — Insider Score 75.0Oct 31 — Insider Score 74.7Nov 1 — Insider Score 74.9Nov 2 — Insider Score 74.9Nov 3 — Insider Score 74.1Nov 4 — Insider Score 73.4Nov 5 — Insider Score 72.6Nov 6 — Insider Score 71.5Nov 7 — Insider Score 71.0Nov 8 — Insider Score 71.4Nov 9 — Insider Score 72.0Nov 10 — Insider Score 70.3Nov 11 — Insider Score 68.6Nov 12 — Insider Score 68.9Nov 13 — Insider Score 67.3Nov 14 — Insider Score 66.3Sep 16Oct 15Nov 14

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.03%

Weight is the stock’s share of each fund’s holdings.